G Luippold

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
    G Luippold
    Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, Biberach an der Riss, Germany
    Diabetes Obes Metab 14:601-7. 2012

Detail Information

Publications1

  1. ncbi Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
    G Luippold
    Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, Biberach an der Riss, Germany
    Diabetes Obes Metab 14:601-7. 2012
    ..This study investigated effects of the SGLT-2 inhibitor, empagliflozin, alone and in combination with insulin, on glucose homeostasis in an animal model of T1DM...